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For the past 5 years genome-wide association studies
(GWAS) have dominated the search for new genes for
complex diseases overtaking other approaches of gene
finding such as candidate gene and linkage analyses.
Facilitated by technological developments in molecular
biology, genetic epidemiologists have so far discovered
many variants associated with several common diseases
and traits such as Type 2 Diabetes, age-related macular
degeneration and Crohn’s disease [1]. There currently are
26 established susceptibility genes published for type 2
diabetes [2], 54 for human height and 22 for lipid levels [3,
4]. These variants still explain only a small part of the
genetic variance or heritability, for human height and lipids
up to 4–6% [5, 6], and subsequently the search for novel
variants continues to unravel ‘missing heritability’.
This missing heritability is explained by additional rare
variants with strong effects and/or common variants with
weak effects, acting additively and/or interacting with
other genetic and environmental variants. To discover these
additional genetic factors, GWAS need to enlarge, and this
has led to further expansion of existing consortia and the
establishment of new ones. Since the first publication in
2005 [7], GWAS have undergone enormous evolution:
from 10,000 single nucleotide polymorphisms (SNPs) in
100 individuals of a single sample [7] to 1 million geno-
typed and*2.5 million imputed SNPs in more than 80,000
individuals of multiple samples [8]. The decreasing costs of
genotyping, new statistical methodologies, and increasing
willingness of the scientists to share and pool data sets have
facilitated these rapid developments and made this
approach very successful also in the setting of epidemiol-
ogy. For instance, the Cohort for Health and Aging
Research (CHARGE) is studying multiple common traits in
50,000–70,000 individuals from US and European follow-
up studies [9–11], and the Dutch three-generation study
LifeLines is going to include 165,000 participants [12].
While increasing size will help in finding new variants
with smaller effects, there will also be true positives that
remain undetected in the larger consortia because of the
stringent threshold levels of statistical significance imposed
in GWAS (P \ 5 9 10-8) to adjust for multiple testing.
The chances of success of consortia are further reduced if
confounding due to population heterogeneity, also refer to
as population admixture, is to be adjusted for, which is the
case when populations are of different genetic origins.
Therefore new approaches are needed to identify genetic
variants explaining the missing heritability and one such
new approach was used successfully in a recent GWAS in
schizophrenia that was published in Nature, online on July
1 [13]. The classical GWAS analysis produced only one
genome-wide significant polymorphism, but the authors
used a new ‘genetic scoring’ method through which they
demonstrated that there indeed existed undetected variants
below the threshold. How to detect variants that are not
detected? Basically, the method tests the association of a
score variable that manifests a combined effect of many
SNPs. The polymorphisms in the score are selected on the
basis of their nominal P value in the predefined discovery
sample. Scores can be generated for any arbitrarily chosen
threshold of nominal statistical significance, for instance
selecting all SNPs with P values lower than e.g. 0.01, 0.1 or
0.5. The significance of the score is then tested by using it
as a predictor in a simple regression model in an inde-
pendent ‘target sample’. In this target sample, a one-
parameter test for all SNPs can be used, thus relaxing the
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conservative P value of 5 9 10-8 needed for testing all
SNPs in GWAS to classical significance level of 0.05.
Using data from the International Schizophrenia Consor-
tium with men defined as the discovery sample and women
as the target sample, the authors showed that a score based
on all SNPs with P \ 0.5 was most strongly and signifi-
cantly correlated with schizophrenia in the target sample
compared to the scores based on other thresholds. The fact
that the set of SNPs with P \ 0.5, including both many
falsely and an unknown number of truly associated SNPs,
predicted better than the score with P \ 5 9 10-8 suggests
that both the number of undetected relevant variants as well
as their joint effect on the outcome is substantial [13]. The
authors further showed that the score correlated signifi-
cantly with related diseases as bipolar disorder, but not
with unrelated outcomes such as Crohn’s disease, coronary
artery disease, hypertension, rheumatoid arthritis or type 1
and type 2 diabetes. This suggests that schizophrenia and
bipolar disorder have a shared genetic component and also
that the selected alleles were specific to schizophrenia and
related disorders [13].
The genetic scoring method is logical and simple as
among the SNPs that fail to reach the significance threshold
in the GWAS there ought to be true associations, which just
do not reach the threshold because the study does not have
enough power [14]. There may, however, be several cave-
ats. First, the informative value of the approach depends on
the size of the discovery sample. If the discovery sample is
small, more falsely associated SNPs will be selected at each
threshold, and consequently scores do not explain much of
the phenotypic variance in the target sample. The second
caveat is that also a score based on 38,000 SNPs with P
value lower than 0.5, derived in a discovery sample of 3,800
individuals, explained only 3% of the heritable variance in
the target population of 3,100 persons. It can be expected
that a larger discovery set will select more true positives
among those with a P value lower than 0.5 and therefore
explain a higher percentage of the variance in the target
sample. However, simulations showed that the variance
explained by the scores can increase from 3 to 20% if the
size of the discovery sample is increased to 20,000 indi-
viduals [13]. Thus, also for this new method the size of the
discovery sample is an important determinant of success.
Third, one of the major conclusions on the basis of this
method is that there are undetected common genetic con-
tributions. Of course one may argue that this observation
could already be inferred from the fact that there is ‘missing
heritability’. But perhaps an even more important limitation
of the genetic scoring method is that it does not tell which
one(s) of the variants included is responsible for the sta-
tistical significance.
Then what can we do with this information? First, the
method may be used to improve our understanding the
genetic architecture of the disease or trait. Scores can be
calculated and tested for multiple different significance
thresholds levels of statistical significance. By comparing
the proportions of explained variance across these thresh-
olds, a pattern may be observed. When going up from a
very low threshold, e.g., P \ 10-7 to P \ 0.5, we may see
that scores may rise to a certain point and then either
decline or become stable, a pattern which suggests that a
few genes with stronger effects may be involved. When the
proportion of explained variance monotonically increases
until all SNPs are included in the scores, there are likely to
be a large number of common variants with small effects.
So the scores calculated over several different cut offs can
give an indication on how complex the trait is, on the
likelihood that the trait has a polygenic basis. For example,
for schizophrenia the score goes up from 0.004 to 0.025 by
moving up from a threshold of P \ 0.01 to P \ 0.5 [13],
which is an indication that many more common low risk
variants are likely involved in schizophrenia.
Second, this method could be considered as an inter-
mediate step in the gene discovery process. When scores
are statistically significant, one may consider to only ana-
lyzing the included SNPs in the independent samples. For
replication purposes this leads to a less stringent level of
statistical significance, and potentially to a higher likeli-
hood of finding susceptibility variants. Because the success
of this approach will depend on the size of the discovery
sample—the larger the discovery sample the more likely
true susceptibility genes will be selected in the scores—its
added value of selecting SNPs in much smaller indepen-
dent populations may not be efficient. More promising is to
use the score approach to select SNPs for use in complex
modeling of the trait for instance to study gene by gene
interactions which otherwise seems impossible with
2.5 million SNPs.
Third, the method could be used to predict disease for
preventive and clinical purposes. Evans and colleagues
applied the score approach and assessed the discriminative
ability for several threshold levels of statistical significance
in several complex diseases [15]. When significance
thresholds were varied from 10-5 to 0.8, discriminative
ability improved for bipolar depression, coronary heart
disease, hypertension and type 2 diabetes, but decreased for
rheumatoid arthritis and type 1 diabetes prediction. For all
diseases, the discriminative ability was lower than what
would be obtained when testing known susceptibility
genes, except for hypertension where no susceptibility
variants were known at the time and for bipolar disorder for
which the score performed better than the known variants,
but only for the liberal and not for the stringent significance
thresholds. It is also suggested that the shared genetic lia-
bility between schizophrenia and bipolar disorder would
make the genetic based refinement of the diagnosis of these
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diseases possible, which may also be tried for other dis-
eases with overlapping symptoms [13]. Of all potential
applications of the genetic scoring method, this is the least
substantiated, and it may still be too premature [16].
However, when the proportion of variance explained by the
scores can increase from 3 to 20%, as suggested by sim-
ulation analyses by improving the power of the discovery
set [13], the discriminative accuracy could be in the range
of what we commonly see for non-genetic risk prediction
models in e.g., cardiovascular diseases, diabetes and mor-
tality [17–19].
GWAS have been very successful in finding multiple
variants for many traits, but we are reaching the limits of
what can be found through this approach sooner or later.
Whether the genetic scoring method will be successful in
finding more risk variants for complex traits and in
unraveling ‘missing heritability’ remains to be determined.
The new genetic score method is one approach, approaches
aiming at testing of more complex models with gene by
gene and gene by environment interactions may be another
avenue. Last but not least technological developments may
come to rescue with new development in high throughput
sequencing.
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